Every now and then, researchers in the medical field are tasked to come up with a drug. This may prove difficult especially if the drug components include protein substrates. It is likely that they conduct protein formulation development and formulation studies which should be complete by the time clinical trials commence.
Formulation studies involve developing a preparation of the drug which is both stable and acceptable to the patient. For orally taken drugs, this usually involves incorporating the drug into a tablet or a capsule. However, a tablet contains a variety of other substances apart from the drug itself, and studies have to be carried out to ensure that the drug is compatible with these other substances
It is also important to consider the competitiveness of the formulation as compared to other products available in the market. This is in terms of the stability of the drug as well as the resources it needs in its development process. This is in light of the fact that proteins have issues pertaining to their stability, which is caused by their delicate structural makeup.
Due to the complexity of its structure, and since it is also very delicate, it is practically impossible to extract a pharmaceutical drug containing only the native and pure protein. The process would prove futile due to inefficiencies from the denatured and degraded protein forms. The very process would prove to be too expensive resource wise.
Maintaining the integrity of this protein would be difficult, even with the extraction of pure strands. The shelf life would be drastically reduced and the instability of the same heightened. The processes of handling and transportation and delivery would need to be done with extreme caution. However, the strand would have the advantage of having neither chemical nor physical change.
The structure of this protein itself is a limiting factor. The three dimensional and naturally delicate nature also keep researchers from easily achieving purity and stability of the strand. In this case, the formulations have to be developed with the allowance that there will be inevitable chemical changes in the nature of particular protein.
With the restrictions facing product development, the focus shifts to determining the degradation and fragmentation associated with the product. This is essentially foretold to avoid problems of losing vital information and product characteristics that are key in the formulation development. Regulatory frameworks also need to be followed to avoid jurisdictional problems.
Various methodical studies need to be carried out to ensure full compliance with regulatory requirements for registration. However, the challenge is that it takes a year or two to collect the results. For efficiency purposes, the commercial formulation should continue in the process of development while preclinical studies and clinical trials are underway.
Commercial formulation should be introduced before the commencement of clinical trials because clinical experience is the most effective way to confirm the safety and efficacy aspects of formulation. In addition, formulations change after this point may introduce formidable challenges to the clinical program and to obtaining regulatory approval.
Formulation studies involve developing a preparation of the drug which is both stable and acceptable to the patient. For orally taken drugs, this usually involves incorporating the drug into a tablet or a capsule. However, a tablet contains a variety of other substances apart from the drug itself, and studies have to be carried out to ensure that the drug is compatible with these other substances
It is also important to consider the competitiveness of the formulation as compared to other products available in the market. This is in terms of the stability of the drug as well as the resources it needs in its development process. This is in light of the fact that proteins have issues pertaining to their stability, which is caused by their delicate structural makeup.
Due to the complexity of its structure, and since it is also very delicate, it is practically impossible to extract a pharmaceutical drug containing only the native and pure protein. The process would prove futile due to inefficiencies from the denatured and degraded protein forms. The very process would prove to be too expensive resource wise.
Maintaining the integrity of this protein would be difficult, even with the extraction of pure strands. The shelf life would be drastically reduced and the instability of the same heightened. The processes of handling and transportation and delivery would need to be done with extreme caution. However, the strand would have the advantage of having neither chemical nor physical change.
The structure of this protein itself is a limiting factor. The three dimensional and naturally delicate nature also keep researchers from easily achieving purity and stability of the strand. In this case, the formulations have to be developed with the allowance that there will be inevitable chemical changes in the nature of particular protein.
With the restrictions facing product development, the focus shifts to determining the degradation and fragmentation associated with the product. This is essentially foretold to avoid problems of losing vital information and product characteristics that are key in the formulation development. Regulatory frameworks also need to be followed to avoid jurisdictional problems.
Various methodical studies need to be carried out to ensure full compliance with regulatory requirements for registration. However, the challenge is that it takes a year or two to collect the results. For efficiency purposes, the commercial formulation should continue in the process of development while preclinical studies and clinical trials are underway.
Commercial formulation should be introduced before the commencement of clinical trials because clinical experience is the most effective way to confirm the safety and efficacy aspects of formulation. In addition, formulations change after this point may introduce formidable challenges to the clinical program and to obtaining regulatory approval.
About the Author:
This worthwhile website has the latest information on protein formulation development that medical workers eagerly want to know about. Simply use the following link to reach the homepage on http://www.freeslate.com.
No comments:
Post a Comment